Hendrik-Tobias Arkenau, MD, PhD, discusses the rationale for using TAS-102 (trifluridine/tipiracil; Lonsurf) as a treatment for patients with gastric cancers.
Hendrik-Tobias Arkenau, MD, PhD, executive medical director, executive medical director for Sarah Cannon Research Institute UK, discusses the rationale for using TAS-102 (trifluridine/tipiracil; Lonsurf) as a treatment for patients with gastric cancers.
Arkenau emphasizes that gastric cancers are one of the most common cancers worldwide and are related to both the third and fifth most common cancers. TAS-102 has shown good clinical evidence in patients with colorectal cancer and patients with gastric or gastroesophageal cancer.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More